Cardio Vascular Disease, Hyperlipidemia
Conditions
Brief summary
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD). Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain. This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.
Interventions
None listed
Sponsors
Chinese University of Hong Kong
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>18 * (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease * (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease
Exclusion criteria
* Inability to provide valid consent by the patient or his legal guardian * Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease. * Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \< 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Low-density lipoprotein cholesterol (LDL-C) level | Baseline | Absolute change in low-density lipoprotein cholesterol (LDL-C) level at baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 12-Item Short Form Survey (SF-12) | Baseline | Patient's quality of life as measured by SF-12 at baseline |
| Rate of major adverse cardiovascular event (MACE) | Baseline | Occurrence of any major adverse cardiovascular event (MACE) at Baseline |
| Rate of subject meeting LDL-C target | Week 26 | Proportion of patients meeting prespecified LDL-C goals (\>50% reduction from baseline) at week 26. |
| Lipid Lowering Therapy adherence | Week 52 | LLT adherence, expressed in proportion of days covered, at week 52 |
| Tolerability of Lipid Lowering Therapy | Week 52 | Rate of adverse drug event reported by subjects on lipid lowering therapy at week 52 |
| Modification of lipid lowering therapy (LLT) | Week 8 | Modification of lipid lowering therapy (LLT) at week 8 |
Countries
Hong Kong
Contacts
Primary ContactGuangming Tan
Outcome results
None listed